Status:
TERMINATED
Treatment of Early Systemic Sclerosis by Bosentan
Lead Sponsor:
Rikshospitalet University Hospital
Conditions:
Systemic Sclerosis (Scleroderma)
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Systemic sclerosis (ssc) is characterised by extensive tissue fibrosis. Using drugs that are capable of inhibiting fibroblast activity may be beneficial if administrered early in the disease course. T...
Detailed Description
Systemic sclerosis (SSc) is characterised by obliterative vasculopathy and extensive fibrosis. The accumulation of extracellular components in the extracellular matrix is mostly due to increased activ...
Eligibility Criteria
Inclusion
- Early systemic sclerosis
Exclusion
- Age \> 70 or \< 18
- Pregnancy
- Nursing
- HIV
- Hb \< 8.5 g/l
- Systolic blood pressure \< 85 mmHg
- Lack of compliance
- Liver disease
- Hypersensitivity to bosentan
- Concurrent us of glibenclamide, ciclosporine A or tacrolimus -
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00226889
Start Date
January 1 2005
End Date
June 1 2009
Last Update
June 12 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of rheumatology, Rikshospitalet
Oslo, Norway, 0026